SCICONX Journal of Vaccine and Immunology

The SCICONX Journal of Vaccine and Immunology (JVI) is a peer‑reviewed scholarly journal dedicated to advancing fundamental, translational, and clinical research at the intersection of vaccinology and immunological sciences. The journal serves as an international platform for scientists, clinicians, public health professionals, and industry researchers to disseminate high‑quality research that deepens understanding of immune mechanisms and accelerates the development, evaluation, and implementation of vaccines.

In an era marked by emerging infectious diseases, evolving pathogens, and rapidly advancing immunotechnologies, the journal aims to bridge basic immunological discovery with real‑world vaccine applications. This journal prioritizes scientific rigor, transparency, and ethical publishing practices while fostering meaningful dialogue across disciplines involved in immune protection and disease prevention.

Aims and Scope

The primary aim of the SCICONX Journal of Vaccine and Immunology is to publish original, impactful research that contributes to the science of immune responses and vaccine development across human and veterinary medicine. The journal welcomes studies that explore immune system dynamics, antigen design, adjuvant innovation, immune correlates of protection, vaccine safety and effectiveness in diverse populations.

The scope of the journal includes, but is not limited to:

• Vaccine design, development, and evaluation
• Immunological mechanisms underlying vaccine‑induced protection
• Novel vaccine platforms and delivery systems
• Immunotherapy and immune modulation strategies
• Clinical trials and real‑world vaccine effectiveness studies
• Host–pathogen interactions and immune evasion
• Vaccines for infectious, non‑infectious, and emerging diseases
• Immunological biomarkers and correlates of immunity
• Vaccine safety, pharmacovigilance, and adverse event monitoring
• Public health immunization strategies and policy‑relevant research

By embracing both foundational science and applied research, the journal seeks to support innovation that informs clinical practice and public health decision‑making.

Journal Focus and Vision

The SCICONX Journal of Vaccine and Immunology is committed to fostering interdisciplinary collaboration and promoting evidence‑based advancements in immune science. The journal encourages submissions that integrate immunology with genomics, bioinformatics, systems biology, nanotechnology, and artificial intelligence where relevant to vaccine research.

Our vision is to become a trusted academic resource that supports global efforts in disease prevention, pandemic preparedness, and immune‑based therapeutics. The journal values originality, methodological soundness, and clarity of scientific communication, ensuring that published research remains accessible and useful to both academic and applied audiences.

The journal publishes a wide range of article types, including:

• Original Research Articles
• Review Articles and Systematic Reviews
• Short Communications
• Clinical Trial Reports
• Methodological and Technical Papers
• Perspectives and Commentaries
• Case‑based Immunological Studies
• Editorials and Special Issue Contributions

All submissions undergo a rigorous peer‑review process to ensure scientific accuracy, relevance, and contribution to the field.

Peer Review and Editorial Standards

The SCICONX Journal of Vaccine and Immunology follows a robust, transparent peer‑review process designed to uphold academic integrity and research quality. Manuscripts are evaluated by independent experts with relevant subject‑matter expertise. Editorial decisions are based solely on scholarly merit, originality, and relevance to the journal’s scope.

The editorial team is committed to maintaining fairness, confidentiality, and timely communication throughout the review and publication process. Conflicts of interest are carefully managed, and ethical compliance is mandatory for all published work.

Fast Editorial Execution and Review Process (FEE-Review Process)

Authors who are willing to publish their articles under this mode can make a pre-payment of € 99 towards express peer-review and editorial decision. First editorial decision in 3 days and final decision with review comments in 5 days from the date of submission. Galley proof generation will be done in next 2 days from acceptance or maximum 5 days (For manuscripts notified for revision by external reviewer).

Manuscripts accepted for publication will be charged regular APC.

Authors retain the copyright of their publication and the final version of the article will be published in both HTML and PDF formats as well as XML formats for transmitting to indexing databases. The editorial team of the Journal will ensure adherence to scientific publication guidelines.

Open Access and Knowledge Dissemination

This journal is dedicated to broad dissemination of scientific knowledge. The journal supports open access publishing to ensure that research findings are freely available to the global scientific community, policymakers, healthcare professionals, and the public. By removing access barriers, the journal aims to enhance visibility, citation potential, and real‑world impact of published research.

Ethics and Publication Integrity

The journal adheres to internationally recognized standards for publication ethics and best practices. Authors are expected to follow ethical guidelines related to research conduct, authorship, data integrity, human and animal research compliance, and conflict of interest disclosure. Allegations of misconduct are addressed transparently and in accordance with established ethical frameworks.

Invitation to Authors and Researchers

The SCICONX Journal of Vaccine and Immunology encourages researchers from academia, clinical settings, public health institutions, and industry to contribute original and thought‑provoking work. Through high editorial standards and a commitment to scientific excellence, the journal seeks to support the advancement of vaccine science and immunology for the benefit of global health.

We welcome submissions that challenge existing paradigms, introduce innovative methodologies, and contribute meaningful insights into immune‑based prevention and therapy.